Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases

Abstract Background The aim of this study was to determine the safety and efficacy of fractionated stereotactic radiotherapy (SRT) in combination with systemic therapies (ST) for brain metastases (BM). Methods Ninety-nine patients (171 BM) received SRT and concurrent ST (group 1) and 95 patients (13...

Full description

Bibliographic Details
Main Authors: Morgan Guénolé, François Lucia, Vincent Bourbonne, Gurvan Dissaux, Emmanuelle Reygagne, Gaëlle Goasduff, Olivier Pradier, Ulrike Schick
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12885-020-07491-z
id doaj-fc5c5bece3584e94b1473d0ab1efd722
record_format Article
spelling doaj-fc5c5bece3584e94b1473d0ab1efd7222020-11-25T03:54:04ZengBMCBMC Cancer1471-24072020-10-0120111110.1186/s12885-020-07491-zImpact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastasesMorgan Guénolé0François Lucia1Vincent Bourbonne2Gurvan Dissaux3Emmanuelle Reygagne4Gaëlle Goasduff5Olivier Pradier6Ulrike Schick7Radiation Oncology Department, University Hospital MorvanRadiation Oncology Department, University Hospital MorvanRadiation Oncology Department, University Hospital MorvanRadiation Oncology Department, University Hospital MorvanRadiation Oncology Department, University Hospital MorvanRadiation Oncology Department, University Hospital MorvanRadiation Oncology Department, University Hospital MorvanRadiation Oncology Department, University Hospital MorvanAbstract Background The aim of this study was to determine the safety and efficacy of fractionated stereotactic radiotherapy (SRT) in combination with systemic therapies (ST) for brain metastases (BM). Methods Ninety-nine patients (171 BM) received SRT and concurrent ST (group 1) and 95 patients (131 BM) received SRT alone without concurrent ST (group 2). SRT was planned on a linear accelerator, using volumetric modulated arc therapy. All ST were allowed including chemotherapy (CT), immunotherapy (IT), targeted therapy (TT) and hormonotherapy (HT). Treatment was considered to be concurrent if the timing between the drug administration and SRT did not exceed 1 month. Local control (LC), freedom for distant brain metastases (FFDBM), overall survival (OS) and radionecrosis (RN) were evaluated. Results After a median follow-up of 11.9 months (range 0.7–29.7), there was no significant difference between the two groups. However, patients who received concurrent IT (n = 30) had better 1-year LC, OS, FFDBM but a higher RN rate compared to patients who did not: 96% versus 78% (p = 0.02), 89% versus 77% (p = 0.02), 76% versus 53% (p = 0.004) and 80% versus 90% (p = 0.03), respectively. In multivariate analysis, concurrent IT (p = 0.022) and tumor volume < 2.07 cc (p = 0.039) were significantly correlated with improvement of LC. The addition of IT to SRT compared to SRT alone was associated with an increased risk of RN (p = 0.03). Conclusion SRT delivered concurrently with IT seems to be associated with improved LC, FFDBM and OS as well as with a higher rate of RN.http://link.springer.com/article/10.1186/s12885-020-07491-zStereotactic radiotherapyBrain metastasesSystemic therapiesImmunotherapyRadioimmunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Morgan Guénolé
François Lucia
Vincent Bourbonne
Gurvan Dissaux
Emmanuelle Reygagne
Gaëlle Goasduff
Olivier Pradier
Ulrike Schick
spellingShingle Morgan Guénolé
François Lucia
Vincent Bourbonne
Gurvan Dissaux
Emmanuelle Reygagne
Gaëlle Goasduff
Olivier Pradier
Ulrike Schick
Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases
BMC Cancer
Stereotactic radiotherapy
Brain metastases
Systemic therapies
Immunotherapy
Radioimmunotherapy
author_facet Morgan Guénolé
François Lucia
Vincent Bourbonne
Gurvan Dissaux
Emmanuelle Reygagne
Gaëlle Goasduff
Olivier Pradier
Ulrike Schick
author_sort Morgan Guénolé
title Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases
title_short Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases
title_full Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases
title_fullStr Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases
title_full_unstemmed Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases
title_sort impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2020-10-01
description Abstract Background The aim of this study was to determine the safety and efficacy of fractionated stereotactic radiotherapy (SRT) in combination with systemic therapies (ST) for brain metastases (BM). Methods Ninety-nine patients (171 BM) received SRT and concurrent ST (group 1) and 95 patients (131 BM) received SRT alone without concurrent ST (group 2). SRT was planned on a linear accelerator, using volumetric modulated arc therapy. All ST were allowed including chemotherapy (CT), immunotherapy (IT), targeted therapy (TT) and hormonotherapy (HT). Treatment was considered to be concurrent if the timing between the drug administration and SRT did not exceed 1 month. Local control (LC), freedom for distant brain metastases (FFDBM), overall survival (OS) and radionecrosis (RN) were evaluated. Results After a median follow-up of 11.9 months (range 0.7–29.7), there was no significant difference between the two groups. However, patients who received concurrent IT (n = 30) had better 1-year LC, OS, FFDBM but a higher RN rate compared to patients who did not: 96% versus 78% (p = 0.02), 89% versus 77% (p = 0.02), 76% versus 53% (p = 0.004) and 80% versus 90% (p = 0.03), respectively. In multivariate analysis, concurrent IT (p = 0.022) and tumor volume < 2.07 cc (p = 0.039) were significantly correlated with improvement of LC. The addition of IT to SRT compared to SRT alone was associated with an increased risk of RN (p = 0.03). Conclusion SRT delivered concurrently with IT seems to be associated with improved LC, FFDBM and OS as well as with a higher rate of RN.
topic Stereotactic radiotherapy
Brain metastases
Systemic therapies
Immunotherapy
Radioimmunotherapy
url http://link.springer.com/article/10.1186/s12885-020-07491-z
work_keys_str_mv AT morganguenole impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
AT francoislucia impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
AT vincentbourbonne impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
AT gurvandissaux impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
AT emmanuellereygagne impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
AT gaellegoasduff impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
AT olivierpradier impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
AT ulrikeschick impactofconcomitantsystemictreatmentsontoxicityandintracerebralresponseafterstereotacticradiotherapyforbrainmetastases
_version_ 1724474974346936320